Takara Bio Inc.

Takahiro Marui

Ikunoshin Kato

Tatsuji Enoki

Hiroaki Sagawa

Fuyuko Takashima

Nobuko Muraki

Kinuko Nagamine

Akiko Kato

Eiji Kobayashi

Toshikazu Nishie

Mitsuko Ideno

Fumiko Iwamoto

The present invention relates to a method for production of a cell population containing a pluripotent stem cell, said method comprising a step of treating a somatic cell which has been contacted with nuclear reprogramming factors under nutrient-starved condition, and/or a step of treating the somatic cell with an agent capable of arresting cell cycle. The present invention allows induction and growth of pluripotent stem cells at high frequency, and it also allows production of pluripotent stem cells with high efficiency. The nuclear reprogramming factors to be used may be any selected from the group consisting of OCT4, SOX2, c-MYC, KLF4, NANOG and LIN28.

Method for production of pluripotent stem cell

A method for transferring a gene into a fat cell or progenitor fat cell comprising the step of infecting the fat cell or progenitor cell with a retrovirus vector having a foreign gene in the presence of a substance having both of a retrovirus-binding site and a target cell-binding site in the molecule or a mixture of a substance having a retrovirus-binding site and a substance having a target cell-binding site, the target cell-binding site having a region that can bind to VLA-5 and/or a region that can bind to VLA-4.

Method for transfer of gene into fat cell or progenitor fat cell

A method for preparing lymphocytes characterized in that the method comprises the step of carrying out expansion in the presence of (a) fibronectin, a fragment thereof or a mixture thereof, (b) a CD3 ligand, and (c) a CD28 ligand.

Method of producing lymphocytes

A method of producing lymphocytes characterized by comprising the step of culturing lymphocytes in the presence of a modified recombinant fibronectin fragment which has overlapping parts of the heparin-binding domain of fibronectin. This method makes it possible to achieve a high cell proliferation rate. The lymphocytes obtained thereby are appropriately usable in, for example, adoptive immunotherapy and, therefore, expected as highly useful in the clinical field. Moreover, a novel modified recombinant fibronectin fragment is provided.

Growing community of inventors

Otsu, Japan

Takahiro Marui